Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C

TA200 Hepatitis C - peginterferon alfa and ribavirin: review decision - December 2013 information

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 112 KB)

TA200 Hepatitis C - peginterferon alfa and ribavirin: review proposal - October 2013 information

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - provisional matrix of stakeholders (PDF 100 KB)

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix B - GE Proposal Paper September 2013 (PDF 534 KB)

200th NICE technology appraisal guidance to help tackle growing hepatitis C problem: press release information

2010/133 200th NICE technology appraisal guidance to help tackle growing hepatitis C problem (PDF 78 KB)

Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination information

Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination (PDF 212 KB)

Hepatitis C - peginterferon alfa and ribavirin: comments on the ACD received from the public through the NICE website (PDF 13 KB)

Hepatitis C - peginterferon alfa and ribavirin: response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 57 KB)

Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination - consultee and commentator comments on the ACD

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Department of Health (PDF 39 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - MSD/Schering Plough (PDF 10 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - NHS Quality Improvement Scotland (PDF 16 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Roche (PDF 39 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Nursing (PDF 23 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Pathologists (PDF 64 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Southampton Health Technology Assessment Centre (PDF 17 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation document information

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: evaluation report

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: overview (PDF 212 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: assessment report (PDF 1.9 MB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: consultee and commentator comments on the assessment report

Consultee and commentator comments on the assessment report: Department of Health (PDF 40 KB)

Consultee and commentator comments on the assessment report: NHS Quality Improvement Scotland (PDF 31 KB)

Consultee and commentator comments on the assessment report: Royal College of Nursing (PDF 44 KB)

Consultee and commentator comments on the assessment report: Royal College of Physicians (PDF 96 KB)

Consultee and commentator comments on the assessment report: Roche (PDF 107 KB)

Consultee and commentator comments on the assessment report: Schering-Plough (PDF 359 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: non-manufacturer submissions

Non-manufacturer submissions: Hepatitis C Trust (PDF 43 KB)

Non-manufacturer submissions: Royal College of Physicians and British Society of Gastroenterology (PDF 103 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: manufacturer submissions (executive summary only)

Manufacturer submissions (executive summary only): Roche (PDF 65 KB)

Manufacturer submissions (executive summary only): Schering-Plough (PDF 66 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: expert written personal statements

Expert written personal statements: Dusheikp (PDF 43 KB)

Expert written personal statements: Gore (PDF 17 KB)

Expert written personal statements: Jose (PDF 62 KB)

Expert written personal statements: Thomas (PDF 10 KB)

Hepatitis C - peginterferon alfa and ribavirin: assessment report (PDF 1.49 MB)

Hepatitis C - peginterferon alfa and ribavirin: final protocol (PDF 123 KB)

Hepatitis C - peginterferon alfa and ribavirin: response to consultee and commentator comments on provisonal matrix (PDF 18 KB)

Hepatitis C - peginterferon alfa and ribavirin: response to consultee and commentator comments on the draft scope (PDF 67 KB)

Hepatitis C - peginterferon alfa and ribavirin: final scope (PDF 35 KB)

Hepatitis C - peginterferon alfa and ribavirin: provisional matrix of consultee and commentators (PDF 38 KB)

Hepatitis C - peginterferon alfa and ribavirin: draft scope (PDF 45 KB)